Invivyd Reports Positive Phase 3 LIBERTY Data for VYD2311
NEW HAVEN, Conn. — September 29, 202 Invivyd announced topline results from the Phase 3 LIBERTY study evaluating VYD2311,...
Monoclonal Antibody
Advertisement
Mirum Advances Brelovitug in Phase 3 HDV Trial
Foster City, California, U.S., September 28, 2026 Mirum Pharmaceuticals has announced a major clinical-development milestone for brelovitug, an investigational...
Eton Launches U.S. Commercial Availability of IMPAVIDO
DEER PARK, Ill. — September 28, 2026 Eton Pharmaceuticals, Inc. announced the U.S. commercial launch of IMPAVIDO® (miltefosine) capsules,...
Tiziana Doses First Participants in ALS Foralumab Trial
BOSTON, Mass. — September 28, 2026 Tiziana Life Sciences, Ltd. announced that the first three participants have been dosed...
Oruka Reports Positive Week 28 ORKA-001 Psoriasis Data
MENLO PARK, Calif. — September 23, 2026 Oruka Therapeutics announced positive Week 28 data from the ongoing EVERLAST-A Phase...
Advertisements
PureTech Gains FDA Fast Track for LYT-200 in HR-MDS
LONDON — September 21, 2026 PureTech Health announced the successful completion of an End-of-Phase 1 meeting with the U.S....
Cue Biopharma Reports Positive Phase 2 CUE-221 Results
BOSTON — September 20, 2026 Cue Biopharma announced positive topline results from a Phase 2 study of CUE-221 (UB-221)...
Tiziana Completes INFORM-MS Phase 2a Trial of Intranasal Foralumab
BOSTON, Mass. — September 21, 2026 Tiziana Life Sciences announced that the last patient has completed the last visit...
AbCellera Presents Phase 2 Data for ABCL635
VANCOUVER, British Columbia — September 16, 2026 AbCellera announced that it will present Phase 2 efficacy and safety data...
Connect Biopharma Advances Rademikibart Toward Phase 3
SAN DIEGO, Calif. — September 15, 2026 Connect Biopharma Holdings Limited announced positive preliminary topline results from the global...
Advertisement
